Login to Your Account

Clinic Roundup

Thursday, May 24, 2012
• Insmed Inc., of Monmouth Junction, N.J., began screening patients for TARGET-NTM (Treatment with ARIKACE to Realize Greater Efficacy Trial), its U.S. Phase II trial of Arikace (liposomal amikacin for inhalation) in nontuberculous mycobacterial lung disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription